BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 He R, Yuan X, Chen Z, Zheng Y. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. International Immunopharmacology 2022;113:109444. [DOI: 10.1016/j.intimp.2022.109444] [Reference Citation Analysis]
2 Khan MI, Batool F, Ali R, Zahra QUA, Wang W, Li S, Wang G, Liu L, Khan SU, Mansoor M, Bilal M, Ding W, Kazmi A, Li F, Qiu B. Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors. Coordination Chemistry Reviews 2022;472:214757. [DOI: 10.1016/j.ccr.2022.214757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 2022;156:113906. [DOI: 10.1016/j.biopha.2022.113906] [Reference Citation Analysis]
4 Mortezaee K, Majidpoor J. Cellular immune states in SARS-CoV-2-induced disease. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1016304] [Reference Citation Analysis]
5 Yu H, Wu M, Chen S, Song M, Yue Y. Biomimetic nanoparticles for tumor immunotherapy. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.989881] [Reference Citation Analysis]
6 Abdolahinia ED, Fathi M, Pirdel Z, Jafari S, Samiei M, Adibkia K, Sefat F, Dizaj SM, Sharifi S. Strategies to improve drug penetration into tumor microenvironment by nanoparticles: focus on nanozymes. OpenNano 2022. [DOI: 10.1016/j.onano.2022.100100] [Reference Citation Analysis]
7 Mortezaee K, Majidpoor J. Extracellular vesicle-based checkpoint regulation and immune state in cancer. Med Oncol 2022;39:225. [PMID: 36175741 DOI: 10.1007/s12032-022-01837-2] [Reference Citation Analysis]
8 Liao W, Li Y, Wang J, Zhao M, Chen N, Zheng Q, Wan L, Mou Y, Tang J, Wang Z. Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy. Int J Nanomedicine 2022;17:4163-93. [PMID: 36134202 DOI: 10.2147/IJN.S380697] [Reference Citation Analysis]
9 Liu T, Cheng S, Xu Q, Wang Z. Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Kaunas) 2022;58:1298. [PMID: 36143975 DOI: 10.3390/medicina58091298] [Reference Citation Analysis]
10 Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol 2022;39:193. [PMID: 36071302 DOI: 10.1007/s12032-022-01801-0] [Reference Citation Analysis]
11 Mohamed Abdoul-latif F, Elmi A, Merito A, Nour M, Risler A, Ainane A, Bignon J, Ainane T. Chemical Analysis of Essential Oils of Cymbopogon schoenanthus (L.) Spreng. and Nepeta azurea R.Br. ex Benth from Djbouti, In-Vitro Cytotoxicity against Cancer Cell Lines and Antibacterial Activities. Applied Sciences 2022;12:8699. [DOI: 10.3390/app12178699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Laskowska AK, Kleczkowska P. Anticancer efficacy of endo- and exogenous potent ligands acting at dopaminergic receptor-expressing cancer cells. Eur J Pharmacol 2022;:175230. [PMID: 36027983 DOI: 10.1016/j.ejphar.2022.175230] [Reference Citation Analysis]
13 Rao D, Yu C, Wang T, Sheng J, Lv E, Liang H, Huang W, Dong H. Pan-cancer analysis combined with experimental validation revealed IL4I1 as an immunological and prognostic biomarker. Int Immunopharmacol 2022;111:109091. [PMID: 35952516 DOI: 10.1016/j.intimp.2022.109091] [Reference Citation Analysis]
14 Hassanian H, Asadzadeh Z, Baghbanzadeh A, Derakhshani A, Dufour A, Rostami Khosroshahi N, Najafi S, Brunetti O, Silvestris N, Baradaran B. The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Front Immunol 2022;13:938063. [DOI: 10.3389/fimmu.2022.938063] [Reference Citation Analysis]
15 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
16 Mortezaee K, Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Med Oncol 2022;39:131. [PMID: 35716327 DOI: 10.1007/s12032-022-01735-7] [Reference Citation Analysis]
17 Bhatia A, Upadhyay AK, Sharma S. miRNAs are now starring in "No Time to Die: Overcoming the chemoresistance in cancer". IUBMB Life 2022. [PMID: 35678612 DOI: 10.1002/iub.2652] [Reference Citation Analysis]
18 Moslehi M, Moazamiyanfar R, Dakkali MS, Rezaei S, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E, Taeb S, Najafi M. Modulation of the immune system by melatonin; implications for cancer therapy. Int Immunopharmacol 2022;108:108890. [PMID: 35623297 DOI: 10.1016/j.intimp.2022.108890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022;27:2259. [PMID: 35408658 DOI: 10.3390/molecules27072259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sisin NNT, Rashid RA, Abdullah R, Razak KA, Geso M, Akasaka H, Sasaki R, Tominaga T, Miura H, Nishi M, Rahman WN. Gafchromic™ EBT3 Film Measurements of Dose Enhancement Effects by Metallic Nanoparticles for 192Ir Brachytherapy, Proton, Photon and Electron Radiotherapy. Radiation 2022;2:130-48. [DOI: 10.3390/radiation2010010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
22 Alesci A, Nicosia N, Fumia A, Giorgianni F, Santini A, Cicero N. Resveratrol and Immune Cells: A Link to Improve Human Health. Molecules 2022;27:424. [PMID: 35056739 DOI: 10.3390/molecules27020424] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
23 Mukherjee S, Madamsetty VS. Organic Nanoparticles in Anti-angiogenic Cancer Therapy. Nanoparticles in Angiogenesis and Cancer 2022. [DOI: 10.1007/978-3-031-11284-3_4] [Reference Citation Analysis]
24 Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed Pharmacother 2021;145:112419. [PMID: 34781146 DOI: 10.1016/j.biopha.2021.112419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]